Breaking News

Andromeda Acquires Teva’s DiaPep277 Rights

By Kristin Brooks | February 24, 2014

Will pursue current Phase III development program in type 1 diabetes

Andromeda Biotech Ltd. has entered an agreement with Teva Pharmaceutical Industries Ltd. to acquire Teva's rights for Andromeda's drug DiaPep277 for the treatment of type 1 diabetes. Teva will transfer its DiaPep277 rights and all of its shares in Andromeda, for total of approximately $72 million, payable in installments through future payments based on Andromeda's revenues or on proceeds payable to its shareholders.
 
Andromeda will work to ensure that the current Phase III development program of DiaPep277 will continue according to plan, without delays in an effort to gain regulatory approval.
 
 
 

Related Contract Manufacturing:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.